The pill is the first known working device capable of non-invasively and accurately assessing the profile of bacterial species inhabiting any stage of the gastrointestinal tract A research team led by Tufts University engineers has developed a 3D printed ingestible pill that samples bacteria found in the gut — known as the microbiome — as it passes through the gastrointestinal…
Read More
MGH will have guaranteed access to ElevateBio BaseCamp’s expert scientists, operators and facilities to accelerate the development of cell and gene therapies for clinical trials MGH makes equity investment in BaseCamp, ElevateBio’s R&D, process development and cGMP manufacturing company BOSTON and CAMBRIDGE, Mass. – July 25, 2019 – Massachusetts General Hospital (MGH) and ElevateBio, a cell and gene therapy holding…
Read More
Abstract Inspired by embryonic wound closure, we present mechanically active dressings to accelerate wound healing. Conventional dressings passively aid healing by maintaining moisture at wound sites. Recent developments have focused on drug and cell delivery to drive a healing process, but these methods are often complicated by drug side effects, sophisticated fabrication, and high cost. Here, we present novel active…
Read More
On its way to being acquired by Bristol-Myers Squibb, Celgene has restructured its three-year-old alliance with Jounce Therapeutics by terminating their up-to-$2.6 billion collaboration to develop multiple cancer immunotherapies, with Celgene instead committing potentially $530 million-plus for global licensing rights to a single Jounce preclinical candidate antibody. The narrower collaboration will see Celgene overseeing all development and commercialization for JTX-8064,…
Read More
Some of the same genes may be involved in different types of epilepsy, pointing the way to possible new treatments Epilepsy is one of the most widespread neurological disorders, but relatively little is known about the genes involved in the more common types. By examining all the genes of over 17,000 people, an international research group has found that more…
Read More
Microfluidics device helps diagnose sepsis in minutes When time matters in hospitals, automated system can detect an early biomarker for the potentially life-threatening condition. Rob Matheson | MIT News Office July 23, 2019 Press Inquiries SHARE COMMENT A novel sensor designed by MIT researchers could dramatically accelerate the process of diagnosing sepsis, a leading cause of death in U.S. hospitals…
Read More
JNDA Submission Represents First Regulatory Submission for Marketing Approval of Vadadustat CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul. 23, 2019– Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that Mitsubishi Tanabe Pharma Corporation (MTPC), its development and commercialization collaboration partner in Japan for vadadustat, Akebia’s investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has submitted a Japanese New Drug Application (JNDA) to the Ministry of Health, Labor and Welfare in Japan for manufacturing and…
Read More
(Credit: Pietro Artoni/Boston Children’s Hospital) Autism and other neurodevelopmental disorders often aren’t diagnosed until a child is a few years of age, when behavioral interventions and speech/occupational therapy become less effective. But new research this week in PNAS suggests that two simple, quantifiable measures — spontaneous fluctuations in pupil dilation or heart rate — could enable much earlier diagnosis of Rett syndrome and possibly other…
Read More
3D InSight™ Human Liver Disease platform provides the most physiologically relevant testing environment for efficacy and safety InSphero 07/19/2019 Schlieren, Switzerland – July 17, 2019   InSphero AG today announced a breakthrough in 3D cell technology for drug discovery and safety testing with the launch of its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The…
Read More